- The FDA grants Orphan Drug status to Gilead Sciences' (GILD +1.2%) simtuzumab for the treatment of primary sclerosing cholengitis, a disease of the bile ducts that causes inflammation and can lead to cirrhosis and liver failure.
- Among the benefits of the Orphan Drug tag is a seven-year period of market exclusivity if approved.
- Gilead is also developing simtuzumab for liver fibrosis and nonalcoholic steatohepatitis (NASH).
Gilead's simtuzumab an Orphan Drug for rare liver disease
Recommended For You
About GILD Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
GILD | - | - |
Gilead Sciences, Inc. |